Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

被引：0

作者：

Franco Maggiolo

Giuliano Rizzardini

Jean-Michel Molina

Federico Pulido

Stephane De Wit

Linos Vandekerckhove

Juan Berenguer

Michelle L. D’Antoni

Christiana Blair

Susan K. Chuck

David Piontkowsky

Hal Martin

Richard Haubrich

Ian R. McNicholl

Joel Gallant

机构：

[1] ASST Papa Giovanni XXIII,Division of Infectious Diseases

[2] Luigi Sacco Hospital,Division of Infectious Diseases

[3] ASST Fatebenefratelli Sacco,School of Clinical Medicine, Faculty of Health Science

[4] University of the Witwatersrand,Department of Infectious Diseases

[5] Saint Louis Hospital,Infectious Diseases

[6] University Paris Diderot,undefined

[7] Unidad VIH,undefined

[8] Hospital Universitario 12 de Octubre,undefined

[9] imas12,undefined

[10] UCM,undefined

[11] St Pierre University Hospital,undefined

[12] Université Libre de Bruxelles,undefined

[13] University Hospital Ghent,undefined

[14] Hospital General Universitario Gregorio Marañón (IiSGM),undefined

[15] Gilead Sciences,undefined

来源：

Infectious Diseases and Therapy | 2021年 / 10卷

关键词：

Age; Bictegravir; Clinical trial; Emtricitabine; HIV; Older; Safety; Tenofovir alafenamide;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：775 / 788

页数：13

共 50 条

[1] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Maggiolo, Franco
Rizzardini, Giuliano
Molina, Jean-Michel
Pulido, Federico
De Wit, Stephane
Vandekerckhove, Linos
Berenguer, Juan
D'Antoni, Michelle L.
Blair, Christiana
Chuck, Susan K.
Piontkowsky, David
Martin, Hal
Haubrich, Richard
McNicholl, Ian R.
Gallant, Joel
INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788
[2] Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
Maggiolo, Franco
Rizzardini, Giuliano
Molina, Jean-Michel
Pulido, Federico
De Wit, Stephane
Vandekerckhove, Linos
Berenguer, Juan
D'Antoni, Michelle L.
Blair, Christiana
Chuck, Susan K.
Piontkowsky, David
Martin, Hal
Haubrich, Richard
McNicholl, Ian R.
Gallant, Joel
HIV MEDICINE, 2023, 24 (01) : 27 - 36
[3] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
Maggiolo, F.
Rizzardini, G.
Molina, J. M.
Pulido, F.
DeWit, S.
Vandekerckhove, L.
Berenguer, J.
D'Antoni, M.
Blair, C.
Chuck, S.
Piontkowsky, D.
Martin, H.
McNicholl, I.
Payne, B.
Gallant, J.
HIV MEDICINE, 2020, 21 : 17 - 17
[4] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged>65 or older: week 48 results from a phase 3b, open-label trial
Maggiolo, F.
Rizzardini, G.
Molina, J-M
Pulido, F.
De Wit, S.
Vandekerckhove, L.
Berenguer, J.
D'Antoni, M.
Blair, C.
Chuck, S.
Piontkowsky, D.
Martin, H.
McNicholl, I.
Haubrich, R.
Gallant, J.
HIV MEDICINE, 2019, 20 : 138 - 138
[5] Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older: Week 72 results from an international, phase IIIb, open-label trial
Maggiolo, F.
Rizzardini, G.
Molina, J.
Pulido, F.
De Wit, S.
Vandekerckhove, L.
Berenguer, J.
D'Antoni, M.
Blair, C.
Chuck, S.
Piontkowsky, D.
Martin, H.
Haubrich, R.
McNicholl, I.
Gallant, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 43 - 44
[6] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
Hagins, Debbie
Kumar, Princy
Saag, Michael
Wurapa, Anson K.
Brar, Indira
Berger, Daniel
Osiyemi, Olayemi
Hileman, Corrilynn O.
Ramgopal, Moti N.
McDonald, Cheryl
Blair, Christiana
Andreatta, Kristen
Collins, Sean E.
Brainard, Diana M.
Martin, Hal
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 86 - 95
[7] Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV a 2/3,-label,-arm study
Rodriguez, Carina A.
Natukunda, Eva
Strehlau, Renate
Venter, Esme L.
Rungmaitree, Supattra
Cunningham, Coleen K.
Lalloo, Umesh
Kosalaraksa, Pope
Hellstroem, Elizabeth
Liberty, Afaaf
Mcgrath, Eric J.
Kaur, Meenu
Leisegang, Rory
Hindman, Jason
Vieira, Vinicius A.
Kersey, Kathryn
Cotton, Mark F.
Rakhmanina, Natella
Gaur, Aditya H.
LANCET HIV, 2024, 11 (05):
[8] Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial
Gaur, Aditya H.
Cotton, Mark F.
Rodriguez, Carina A.
McGrath, Eric J.
Helstrom, Elizabeth
Liberty, Afaaf
Natukunda, Eva
Kosalaraksa, Pope
Chokephaibulkit, Kulkanya
Maxwell, Heather
Wong, Pamela
Porter, Danielle
Majeed, Sophia
Yue, Mun Sang
Graham, Hiba
Martin, Hal
Brainard, Diana M.
Pikora, Cheryl
LANCET CHILD & ADOLESCENT HEALTH, 2021, 5 (09): : 642 - 651
[9] Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations
Chang Ziwei
Zhu Hongyan
Zhang Yiting
Chen Yaling
Li Jiahui
Qin Jiamin
Zhu Yueping
Wei Hongxia
Yang Yongfeng
Zou Meiyin
Qian Feng
Hu Zhiliang
中华医学杂志英文版, 2024, 137 (22)
[10] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Arribas, Jose R.
Pialoux, Gilles
Gathe, Joseph
Di Perri, Giovanni
Reynes, Jacques
Tebas, Pablo
Thai Nguyen
Ebrahimi, Ramin
White, Kirsten
Piontkowsky, David
LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 581 - 589

← 1 2 3 4 5 →